Achalasia: A review of therapeutic options and outcomes

Comprehensive Therapy

Volumn 28, Issue 1, 2002, Pages 15-22

  Da Silveira, Eduardo B V ^a   Rogers, Arvey I ^b  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

BLEEDING; ESOPHAGITIS; ESOPHAGUS ACHALASIA; ESOPHAGUS DILATATION; ESOPHAGUS MYOTOMY; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RASH; REVIEW; THORAX PAIN;

EID: 0036198934     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-002-0038-4     Document Type: Review

References (53)

1. Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction
2. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia
3. Nitric oxide: A mediator of esophageal motor function
4. Endoscopic ultrasound: A new look at achalasia?
5. Endosonographic evaluation of the patient with achalasia
6. High- and low-compliance balloon dilators in patients with achalasia: A randomized prospective comparative trial
7. Pneumatic dilation for achalasia: Are all complications revealed?
8. Complications during pneumatic dilation for achalasia or diffuse esophageal spasm. Analysis of risk factors, early clinical characteristics, and outcome
9. Conservative management of esophageal nontransmural tears after pneumatic dilation for achalasia
10. Gastroesophageal reflux in achalasia. When is reflux really reflux?
11. Effect of pneumatic dilation on gastroesophageal reflux in achalasia
12. Achalasia: Prospective evaluation of relationship between lower esophageal sphincter pressure, esophageal transit, and esophageal diameter and symptoms in response to pneumatic dilation
13. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: A randomised trial
14. Individual prediction of response to pneumatic dilation in patients with achalasia
15. To dilate or to operate? That is the question
16. Graded pneumatic dilatation using Rigiflex achalasia dilator in patients with primary esophageal achalasia
17. Idiosyncratic adverse reactions to intramuscular Botulinum toxin type A injection
18. Predictors of outcome in patients with achalasia treated by pneumatic dilation
19. Pneumatic balloon dilation in achalasia: A prospective comparison of balloon distention time
20. Pneumatic dilatation is effective long-term treatment for achalasia
21. Choice of therapy for achalasia in relation to age
22. Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus
23. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission
24. Neurotrophic regulation of muscle cholinesterase: Effects of botulinum toxin and denervation
25. Therapeutic uses of botulinum toxin
26. Early terminal and nodal sprouting of motor axons after botulinum toxin
27. Botulinum toxin treatment of tremors
28. Treatment of spasticity with botulinum toxin: A double-blind study
29. Human response to Botulinum toxin injection: Type B compared with type A
30. Medical therapy of achalasia: A benefit reserved for few
31. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia
32. Botox injection for achalasia: A modified technique
33. Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia
34. Use of high-resolution endoscopic ultrasonography to assess wall damage after pneumatic dilation and botulinum toxin injection to treat achalasia
35. Recent advances in the treatment of achalasia
36. Intrasphincteric botulinum toxin for the treatment of achalasia
37. Treatment of achalasia with intrasphincteric injection of botulin toxin. A pilot trial
38. Botulinum toxin versus pneumatic dilatation in achalasia: Results of a multicentre controlled trial
39. Botulinum toxin injections for achalasia symptoms can approximate the short-term efficacy of a single pneumatic dilation: A survival analysis approach
40. Botulinum toxin for achalasia: Long-term outcome and predictors of response
41. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter
42. Treatment of achalasia in Chagas' disease with botulinum toxin
43. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies - Therapeutic consequences
44. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes
45. Results of Heller's operation for achalasia of the oesophagus. The importance of hiatal repair
46. Laparoscopic Heller's cardiomyotomy in achalasia. Is intraoperative endoscopy useful, and why?
47. Achalasia: A prospective study comparing the results of dilatation and myotomy
48. Surgical complications of Chagas' disease: Megaesophagus, achalasia of the pylorus, and cholelithiasis
49. Comparison of outcomes following open and laparoscopic esophagomyotomy for achalasia
50. Laparoscopic esophageal myotomy and anterior partial fundoplication for the treatment of achalasia
51. Late results of a prospective randomised study comparing forceful dilatation and oesophagomyotomy in patients with achalasia
52. Laparoscopic Heller myotomy relieves dysphagia in achalasia when the esophagus is dilated
53. Pneumatic dilation in achalasia with a low-compliance balloon: Results of a 5-year prospective evaluation